WINSTON-SALEM, N.C., June 23, 2009 (GLOBE NEWSWIRE) -- Charter Medical, Ltd., a division of Lydall, Inc. (NYSE:LDL), is pleased to announce today that their 501(k) cleared CELL-FREEZE(r) cryogenic storage containers were approved by Dana-Farber Cancer Institute in Boston, MA. CELL-FREEZE(r) was designed for peripherally derived stem cells and used for cryogenic temperature applications as low as -196 degrees Celsius for storage, preservation and transfer. Dana-Farber Cancer Institute, a national leader in adult and pediatric cancer care and research, will be using CELL-FREEZE(r) for stem cell applications.
Peter Ferris, President of Charter Medical, Ltd. states, "We are pleased Dana-Farber Cancer Institute, a world class cancer research center, selected CELL-FREEZE(r) for stem cell clinical applications. We are encouraged by market acceptance of CELL-FREEZE(r) and currently have our product being evaluated at over 30 stem cell research centers across North America."
Lydall, Inc. is a New York Stock Exchange listed company, headquartered in Manchester, Connecticut. The Company, with operations in the U.S., France, Germany, and The Netherlands and sales offices in Europe and Asia, focuses on specialty engineered products for the thermal/acoustical, biomedical, and filtration/separation markets. For more information, please visit www.lydall.com.
Charter Medical, Ltd. headquarters and manufacturing facility are located in Winston-Salem, North Carolina. Learn more about Charter Medical at www.chartermedical.com.
The Lydall, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=6235